WBR249: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{WBRQuestion |QuestionAuthor=Gerald Chi |ExamType=USMLE Step 1 |MainCategory=Microbiology, Pharmacology |SubCategory=Pulmonology |MainCategory=Microbiology, Pharmacology |Sub...")
 
m (refreshing WBR questions)
 
(3 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor=Gerald Chi
|QuestionAuthor=Gerald Chi (Reviewed by  {{YD}})
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Microbiology, Pharmacology
|MainCategory=Pharmacology
|SubCategory=Pulmonology
|SubCategory=Pulmonology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Pharmacology
|SubCategory=Pulmonology
|SubCategory=Pulmonology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Pharmacology
|SubCategory=Pulmonology
|SubCategory=Pulmonology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Pharmacology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|SubCategory=Pulmonology
|SubCategory=Pulmonology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Pharmacology
|SubCategory=Pulmonology
|SubCategory=Pulmonology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Pharmacology
|SubCategory=Pulmonology
|SubCategory=Pulmonology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Pharmacology
|SubCategory=Pulmonology
|SubCategory=Pulmonology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Pharmacology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Pharmacology
|SubCategory=Pulmonology
|SubCategory=Pulmonology
|Prompt=A 32-year-old homosexual intravenous drug user is admitted with a worsening respiratory distress accompanied by fever and nonproductive cough. Arterial blood gas values are pH 7.52, PaCO2 28 mm Hg, HCO3 22 mEq/L, and PaO2 70 mm Hg when breathing room air. His CD4+ count is 150 cells per microliter. Chest X-ray reveals bilateral perihilar interstitial infiltrates suggesting an infection etiology. The causative organism is detected in bronchoalveolar lavage with silver stain. Two days after therapy, he starts to have dizziness, headache, coldness in hands and feet, pale skin, and chest pain. Peripheral blood smear shows irregularly fragmented erythrocytes. Supravital stain of the smear shows immature red cells with dark blue dots and curved linear structures in the cytoplasm. Which of the following medications is most likely to be the cause of his symptoms?
|Prompt=A 32-year-old man with a history of intravenous drug use is admitted with a worsening respiratory distress accompanied by fever and nonproductive cough. Arterial blood gas values are pH=7.52, PaCO2=28 mm Hg, HCO3=22 mEq/L, and PaO2=70 mm Hg when breathing room air. The patient's CD4+ count is 145 cells per microliter. Chest X-ray demonstrates bilateral perihilar interstitial infiltrates suggive of an infectious etiology. The causative organism is detected in bronchoalveolar lavage with silver stain. Two days following pharmacologic therapy, the patient returns to the emergency department with chest pain, dizziness, headache, cold extremities, and pale skin. Peripheral blood smear is remarkable for irregularly fragmented erythrocytes. Supravital stain of the smear demonstrates immature red blood cells with dark blue dots and curved linear structures in the cytoplasm. Which of the following drugs is most likely to be responsible for this patient's readmission?
|Explanation=''Pneumocystis jiroveci''/''carinii'' pneumonia (PCP) is an opportunistic infection caused by ''Pneumocystis jiroveci''. The risk of PCP increases among HIV-positive patients when CD4+ cell concentrations are less than 200 cells/μl. Symptoms include fever, non-productive cough, shortness of breath, weight loss, and night sweats. Chest films typically demonstrate diffuse, symmetrical, perihilar interstitial infiltration that may progress to a homogenous, ground-glass opacification of the lung fields.


|Explanation=Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jirovecii. The risk of PCP increases when CD4+ cell levels are less than 200 cells/μl. Symptoms include fever, non-productive cough, shortness of breath, weight loss, and night sweats. Chest films typically show diffuse, symmetrical, perihilar interstitial infiltration that may progress to a homogenous, ground-glass opacification of lung fields.
Hypoxemia, the most characteristic laboratory abnormality, may range from mild (room air arterial oxygen ≥70 mm Hg or alveolar-arterial O2 difference <35 mm Hg) to moderate (A-a DO2 ≥35 and <45 mm Hg) to severe (A-a DO2 ≥45 mm Hg).
 
 
Hypoxemia, the most characteristic laboratory abnormality, can range from mild (room air arterial oxygen ≥70 mm Hg or alveolar-arterial O2 difference <35 mm Hg) to moderate (A-a DO2 ≥35 and <45 mm Hg) to severe (A-a DO2 ≥45 mm Hg).
 
 
TMP-SMX is the treatment of choice for PCP. For mild-to-moderate disease, alternative therapeutic regimens include: dapsone plus TMP, primaquine plus clindamycin, and atovaquone. For moderate-to-severe disease, clindamycin-primaquine or pentamidine can be used. Patients with moderate-to-severe disease should receive adjunctive corticosteroids as early as possible and certainly within 72 hours after starting specific PCP therapy.
 
 
His hospital course is complicated by hemolytic anemia due to increased oxidative stress, which typically occurs in patients with glucose-6-phosphate dehydrogenase deficiency. Heinz bodies, bite cells, spherocytes, and reticulocytes may be evident on peripheral blood smear.


TMP-SMX is the treatment of choice for PCP. For mild-to-moderate disease, alternative therapeutic regimens include either dapsone plus TMP, primaquine plus clindamycin, or atovaquone. For moderate-to-severe disease, either clindamycin-primaquine or pentamidine may be administered. Patients with moderate-to-severe disease should receive adjunctive corticosteroids as early as possible within 72 hours after starting specific PCP therapy.
This patient's hospital course is complicated by hemolytic anemia due to increased oxidative stress, which typically occurs among patients with glucose-6-phosphate dehydrogenase deficiency. Heinz bodies, bite cells, spherocytes, and reticulocytes may be evident on peripheral blood smear.
|AnswerA=Atovaquone
|AnswerA=Atovaquone
 
|AnswerAExp=For mild-to-moderate PCP alternative therapeutic regimens include either dapsone plus TMP, primaquine plus clindamycin, or atovaquone. However, atovaquone generally does not cause hemolytic anemia.
|AnswerAExp='''Incorrect'''<BR>For mild-to-moderate PCP, alternative therapeutic regimens include: dapsone plus TMP, primaquine plus clindamycin, and atovaquone. However, atovaquone generally does not cause hemolytic anemia.
 
|AnswerB=Clindamycin
|AnswerB=Clindamycin
|AnswerBExp='''Incorrect'''<BR>For mild-to-moderate disease, alternative therapeutic regimens include: dapsone plus TMP, primaquine plus clindamycin, and atovaquone. However, clindamycin generally does not cause hemolytic anemia.
|AnswerBExp=For mild-to-moderate PCP, alternative therapeutic regimens include dapsone plus TMP, primaquine plus clindamycin, or atovaquone. However, clindamycin generally does not cause hemolytic anemia.
|AnswerC=Methylprednisolone
|AnswerC=Methylprednisolone
|AnswerCExp='''Incorrect'''<BR>Patients with moderate-to-severe disease should receive adjunctive corticosteroids as early as possible and certainly within 72 hours after starting specific PCP therapy. However, methylprednisolone generally does not cause hemolytic anemia.
|AnswerCExp=Patients with moderate-to-severe PCP should receive adjunctive corticosteroids as early as possible within 72 hours after starting specific PCP therapy. However, methylprednisolone generally does not cause hemolytic anemia.
 
|AnswerD=Pentamidine
|AnswerD=Pentamidine
 
|AnswerDExp=For moderate-to-severe PCP, either clindamycin-primaquine or pentamidine may be administered. However, pentamidine generally does not cause hemolytic anemia.
|AnswerDExp='''Incorrect'''<BR>For moderate-to-severe disease, clindamycin-primaquine or pentamidine can be used. However, pentamidine generally does not cause hemolytic anemia.
 
|AnswerE=Primaquine
|AnswerE=Primaquine
 
|AnswerEExp=For mild-to-moderate PCP, alternative therapeutic regimens include either dapsone plus TMP, primaquine plus clindamycin, or atovaquone. Common triggers of hemolytic anemia include sulfonamides and other drugs such as chloroquine, isoniazid, nalidixic acid, nitrofurantoin, and primaquine.
|AnswerEExp='''Correct'''<BR>For mild-to-moderate disease, alternative therapeutic regimens include: dapsone plus TMP, primaquine plus clindamycin, and atovaquone. Common triggers of hemolytic anemia include sulfonamides and other drugs such as chloroquine, isoniazid, nalidixic acid, nitrofurantoin, and primaquine.
|EducationalObjectives=For mild-to-moderate PCP, alternative therapeutic regimens include either dapsone plus TMP, primaquine plus clindamycin, or atovaquone. Common triggers of hemolytic anemia include sulfonamides and other drugs such as chloroquine, isoniazid, nalidixic acid, nitrofurantoin, and primaquine.
 
|References=Kaplan JE, Benson C, Holmes KK, et al. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Centers for Prevention and Disease Control. 2009;58(RR04);1-198.<br>
First Aid 2015 page 168, 170.
|RightAnswer=E
|RightAnswer=E
|Approved=No
|WBRKeyword=Pneumocystis jiroveci, HIV, PCP, Pneumocystis carinii pneumonia, Dapsone, Antimicrobial therapy
|Approved=Yes
}}
}}

Latest revision as of 02:53, 28 October 2020

 
Author [[PageAuthor::Gerald Chi (Reviewed by Yazan Daaboul, M.D.)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pharmacology
Sub Category SubCategory::Pulmonology
Prompt [[Prompt::A 32-year-old man with a history of intravenous drug use is admitted with a worsening respiratory distress accompanied by fever and nonproductive cough. Arterial blood gas values are pH=7.52, PaCO2=28 mm Hg, HCO3=22 mEq/L, and PaO2=70 mm Hg when breathing room air. The patient's CD4+ count is 145 cells per microliter. Chest X-ray demonstrates bilateral perihilar interstitial infiltrates suggive of an infectious etiology. The causative organism is detected in bronchoalveolar lavage with silver stain. Two days following pharmacologic therapy, the patient returns to the emergency department with chest pain, dizziness, headache, cold extremities, and pale skin. Peripheral blood smear is remarkable for irregularly fragmented erythrocytes. Supravital stain of the smear demonstrates immature red blood cells with dark blue dots and curved linear structures in the cytoplasm. Which of the following drugs is most likely to be responsible for this patient's readmission?]]
Answer A AnswerA::Atovaquone
Answer A Explanation AnswerAExp::For mild-to-moderate PCP alternative therapeutic regimens include either dapsone plus TMP, primaquine plus clindamycin, or atovaquone. However, atovaquone generally does not cause hemolytic anemia.
Answer B AnswerB::Clindamycin
Answer B Explanation AnswerBExp::For mild-to-moderate PCP, alternative therapeutic regimens include dapsone plus TMP, primaquine plus clindamycin, or atovaquone. However, clindamycin generally does not cause hemolytic anemia.
Answer C AnswerC::Methylprednisolone
Answer C Explanation AnswerCExp::Patients with moderate-to-severe PCP should receive adjunctive corticosteroids as early as possible within 72 hours after starting specific PCP therapy. However, methylprednisolone generally does not cause hemolytic anemia.
Answer D AnswerD::Pentamidine
Answer D Explanation AnswerDExp::For moderate-to-severe PCP, either clindamycin-primaquine or pentamidine may be administered. However, pentamidine generally does not cause hemolytic anemia.
Answer E AnswerE::Primaquine
Answer E Explanation [[AnswerEExp::For mild-to-moderate PCP, alternative therapeutic regimens include either dapsone plus TMP, primaquine plus clindamycin, or atovaquone. Common triggers of hemolytic anemia include sulfonamides and other drugs such as chloroquine, isoniazid, nalidixic acid, nitrofurantoin, and primaquine.]]
Right Answer RightAnswer::E
Explanation [[Explanation::Pneumocystis jiroveci/carinii pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jiroveci. The risk of PCP increases among HIV-positive patients when CD4+ cell concentrations are less than 200 cells/μl. Symptoms include fever, non-productive cough, shortness of breath, weight loss, and night sweats. Chest films typically demonstrate diffuse, symmetrical, perihilar interstitial infiltration that may progress to a homogenous, ground-glass opacification of the lung fields.

Hypoxemia, the most characteristic laboratory abnormality, may range from mild (room air arterial oxygen ≥70 mm Hg or alveolar-arterial O2 difference <35 mm Hg) to moderate (A-a DO2 ≥35 and <45 mm Hg) to severe (A-a DO2 ≥45 mm Hg).

TMP-SMX is the treatment of choice for PCP. For mild-to-moderate disease, alternative therapeutic regimens include either dapsone plus TMP, primaquine plus clindamycin, or atovaquone. For moderate-to-severe disease, either clindamycin-primaquine or pentamidine may be administered. Patients with moderate-to-severe disease should receive adjunctive corticosteroids as early as possible within 72 hours after starting specific PCP therapy. This patient's hospital course is complicated by hemolytic anemia due to increased oxidative stress, which typically occurs among patients with glucose-6-phosphate dehydrogenase deficiency. Heinz bodies, bite cells, spherocytes, and reticulocytes may be evident on peripheral blood smear.
Educational Objective: For mild-to-moderate PCP, alternative therapeutic regimens include either dapsone plus TMP, primaquine plus clindamycin, or atovaquone. Common triggers of hemolytic anemia include sulfonamides and other drugs such as chloroquine, isoniazid, nalidixic acid, nitrofurantoin, and primaquine.
References: Kaplan JE, Benson C, Holmes KK, et al. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Centers for Prevention and Disease Control. 2009;58(RR04);1-198.
First Aid 2015 page 168, 170.]]

Approved Approved::Yes
Keyword WBRKeyword::Pneumocystis jiroveci, WBRKeyword::HIV, WBRKeyword::PCP, WBRKeyword::Pneumocystis carinii pneumonia, WBRKeyword::Dapsone, WBRKeyword::Antimicrobial therapy
Linked Question Linked::
Order in Linked Questions LinkedOrder::